KalVista Pharmaceuticals, Inc. (KALV)
NASDAQ: KALV · Real-Time Price · USD
11.32
-0.18 (-1.57%)
At close: Oct 13, 2025, 4:00 PM EDT
11.16
-0.16 (-1.41%)
After-hours: Oct 13, 2025, 6:14 PM EDT
KalVista Pharmaceuticals Revenue
KalVista Pharmaceuticals had revenue of $1.43M in the quarter ending July 31, 2025. This brings the company's revenue in the last twelve months to $1.43M.
Revenue (ttm)
$1.43M
Revenue Growth
n/a
P/S Ratio
397.53
Revenue / Employee
$5,281
Employees
270
Market Cap
571.92M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Apr 30, 2025 | - | - | - |
Apr 30, 2024 | - | - | - |
Apr 30, 2023 | - | - | - |
Apr 30, 2022 | - | - | - |
Apr 30, 2021 | - | - | - |
Apr 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Apr 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Apr 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Apr 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Apr 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
KALV News
- 7 days ago - KalVista Pharmaceuticals Presents New Data Highlighting the Potential of EKTERLY® (sebetralstat) to Transform On-Demand Hereditary Angioedema Treatment in Europe - Business Wire
- 7 days ago - KalVista Pharmaceuticals Appoints Bilal Arif as Chief Operating Officer and Linea Aspesi as Chief People Officer - Business Wire
- 10 days ago - KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 11 days ago - KalVista Pharmaceuticals Announces Appointment of Bethany L. Sensenig to Board of Directors - Business Wire
- 17 days ago - KalVista Pharmaceuticals to Present New EKTERLY® (sebetralstat) Data at the 20th German Allergy Congress - Business Wire
- 18 days ago - KalVista Prices Upsized Offering of $125.0 Million of 3.250% Convertible Senior Notes Due 2031 - Business Wire
- 19 days ago - KalVista Pharmaceuticals Announces Proposed Offering of $110.0 Million of Convertible Senior Notes - Business Wire
- 24 days ago - KalVista Pharmaceuticals Announces European Commission and Swissmedic Approval of EKTERLY® (sebetralstat), First and Only Oral On-Demand Treatment for Hereditary Angioedema - Business Wire